伊朗最高領袖穆傑塔巴·哈梅內伊：外國勢力唯一的歸宿就是葬身海底。

Beijing Business Daily says the A-share market is driven by reallocation among existing funds, with frequent sector rotation. Although indices have posted a choppy rebound, the absence of coordinated capital flows makes a broad-based rally unlikely. Overall market capital remains stable but cannot cover all sectors and names; persistent structural divergence and sector-led rallies will be the prevailing market feature, requiring investors to adjust positioning.

China's National Medical Products Administration (NMPA) on Oct. 19 met to advance its AI + drug regulation agenda, directing regulators to set rules, steady expectations, enhance services and build an AI-enabled ecosystem to support pharmaceutical innovation. The NMPA said it will draft special plans to back priority tracks, shift review services upstream toward innovators, and create an innovation-encouraging yet prudently risk-aware regulatory environment; it called for using AI to improve drug-safety governance—making reviews smarter, inspections and enforcement more precise, risk controls more sensitive and coordinated supervision more efficient—and for establishing a full-lifecycle, continuously iterated AI application management mechanism, centralizing resources, training specialist talent, promoting technology-for-good and safeguarding AI security standards.